Guobang Pharma Ltd.
SSE:605507.SS
20.53 (CNY) • At close June 9, 2025
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2025 Q1 | 2024 Q4 | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 | 2022 Q4 | 2022 Q3 | 2022 Q2 | 2022 Q1 | 2021 Q4 | 2021 Q3 | 2021 Q2 | 2021 Q1 | 2020 Q4 | 2020 Q3 | 2020 Q2 | 2020 Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 1,440.056 | 1,472.692 | 1,525.791 | 1,541.255 | 1,338.703 | 1,295.971 | 1,243.757 | 1,399.558 | 1,410.163 | 1,607.576 | 1,409.88 | 1,527.37 | 1,176.098 | 1,292.149 | 970.805 | 1,100.13 | 1,142.266 | 1,059.904 | 1,014.846 | 1,232.281 | 899.287 |
| Cost of Revenue
| 1,059.33 | 1,156.104 | 1,138.893 | 1,173.754 | 971.461 | 1,042.948 | 936.697 | 1,082.572 | 1,034.901 | 1,198.942 | 1,042.83 | 1,092.474 | 810.636 | 928.669 | 666.378 | 751.111 | 801.464 | 729.852 | 641 | 776.02 | 608.58 |
| Gross Profit
| 380.726 | 316.588 | 386.897 | 367.501 | 367.242 | 253.023 | 307.06 | 316.985 | 375.261 | 408.634 | 367.05 | 434.897 | 365.462 | 363.48 | 304.427 | 349.02 | 340.802 | 330.052 | 373.845 | 456.261 | 290.707 |
| Gross Profit Ratio
| 0.264 | 0.215 | 0.254 | 0.238 | 0.274 | 0.195 | 0.247 | 0.226 | 0.266 | 0.254 | 0.26 | 0.285 | 0.311 | 0.281 | 0.314 | 0.317 | 0.298 | 0.311 | 0.368 | 0.37 | 0.323 |
| Reseach & Development Expenses
| 38.738 | 54.764 | 67.328 | 52.297 | 37.655 | 27.75 | 65.323 | 50.581 | 46.857 | 62.482 | 48.453 | 54.952 | 31.655 | 49.06 | 37.774 | 35.475 | 32.963 | 40.26 | 34.348 | 38.873 | 23.705 |
| General & Administrative Expenses
| 84.761 | -138.363 | 180.612 | -30.226 | 75.746 | -126.169 | 182.472 | -29.246 | 76.324 | -117.776 | 167.884 | -23.859 | 65.253 | -94.107 | 69.148 | 97.476 | 19.053 | -88.958 | 58.592 | 47.649 | 42.906 |
| Selling & Marketing Expenses
| 17.759 | -5.022 | 30.896 | 15.018 | 17.227 | 20.347 | 21.36 | 17.15 | 15.342 | 25.003 | 13.45 | 10.908 | 14.792 | 0.694 | 21.553 | 18.849 | 14.769 | 19.121 | 16.812 | 23.426 | 15.528 |
| SG&A
| 102.52 | -143.385 | 95.342 | 80.178 | 92.974 | -105.822 | 203.832 | -12.096 | 91.666 | -92.773 | 181.334 | -12.95 | 80.045 | -93.413 | 90.7 | 116.324 | 33.823 | -69.837 | 75.404 | 71.075 | 58.434 |
| Other Expenses
| -9.009 | 184.089 | -93.426 | -35.708 | -2.082 | 10.132 | 1.13 | -3.637 | 6.452 | 206.604 | -77.932 | 90.107 | 3.085 | -5.996 | 6.75 | -1.974 | -0.772 | 7.73 | -0.305 | 4.301 | -4.405 |
| Operating Expenses
| 132.248 | 95.468 | 185.409 | 168.183 | 133.667 | 129.342 | 168.149 | 150.718 | 144.975 | 176.313 | 151.856 | 132.109 | 114.785 | 122.256 | 132.032 | 119.619 | 105.079 | 108.722 | 113.51 | 114.485 | 84.14 |
| Operating Income
| 248.478 | 221.12 | 201.488 | 199.318 | 236.105 | 138.288 | 146.46 | 186.965 | 230.551 | 212.546 | 261.713 | 339.033 | 239.587 | 211.692 | 157.313 | 218.538 | 221.232 | 178.887 | 227.423 | 338.695 | 191.111 |
| Operating Income Ratio
| 0.173 | 0.15 | 0.132 | 0.129 | 0.176 | 0.107 | 0.118 | 0.134 | 0.163 | 0.132 | 0.186 | 0.222 | 0.204 | 0.164 | 0.162 | 0.199 | 0.194 | 0.169 | 0.224 | 0.275 | 0.213 |
| Total Other Income Expenses Net
| 0.35 | 2.218 | -0.945 | -6.288 | -2.082 | -0.19 | 0.185 | -2.692 | -1.918 | -7.342 | 0.588 | -5.718 | -4.484 | -5.996 | 6.75 | -1.974 | -0.772 | 7.73 | -0.305 | 4.301 | -4.405 |
| Income Before Tax
| 248.829 | 223.337 | 200.543 | 229.824 | 234.024 | 138.098 | 146.644 | 184.273 | 228.633 | 205.203 | 262.301 | 333.032 | 235.103 | 205.696 | 164.062 | 216.564 | 220.46 | 186.617 | 227.119 | 342.996 | 186.706 |
| Income Before Tax Ratio
| 0.173 | 0.152 | 0.131 | 0.149 | 0.175 | 0.107 | 0.118 | 0.132 | 0.162 | 0.128 | 0.186 | 0.218 | 0.2 | 0.159 | 0.169 | 0.197 | 0.193 | 0.176 | 0.224 | 0.278 | 0.208 |
| Income Tax Expense
| 34.569 | 21.398 | 26.274 | 24.275 | 35.445 | 15.775 | 15.845 | 22.388 | 33.662 | 5.937 | 35.94 | 38.344 | 34.797 | 21.115 | 20.445 | 23.891 | 35.101 | 13.895 | 35.641 | 57.969 | 25.643 |
| Net Income
| 214.977 | 202.71 | 174.287 | 205.867 | 198.731 | 123.391 | 131.602 | 162.841 | 194.629 | 199.84 | 226.026 | 294.644 | 200.395 | 184.947 | 143.393 | 192.59 | 185.1 | 172.745 | 190.631 | 285.286 | 161.339 |
| Net Income Ratio
| 0.149 | 0.138 | 0.114 | 0.134 | 0.148 | 0.095 | 0.106 | 0.116 | 0.138 | 0.124 | 0.16 | 0.193 | 0.17 | 0.143 | 0.148 | 0.175 | 0.162 | 0.163 | 0.188 | 0.232 | 0.179 |
| EPS
| 0.38 | 0.36 | 0.32 | 0.37 | 0.36 | 0.22 | 0.24 | 0.29 | 0.35 | 0.36 | 0.41 | 0.53 | 0.36 | 0.33 | 0.3 | 0.41 | 0.39 | 0.36 | 0.4 | 0.6 | 0.34 |
| EPS Diluted
| 0.38 | 0.36 | 0.32 | 0.37 | 0.36 | 0.22 | 0.24 | 0.29 | 0.35 | 0.36 | 0.41 | 0.53 | 0.36 | 0.33 | 0.3 | 0.41 | 0.39 | 0.36 | 0.4 | 0.6 | 0.34 |
| EBITDA
| 254.445 | 228.98 | 207.405 | 340.076 | 345.043 | 224.139 | 239.854 | 266.307 | 312.243 | 280.24 | 342.389 | 395.091 | 296.998 | 237.069 | 185.424 | 278.057 | 236.192 | 208.055 | 234.117 | 386.992 | 225.697 |
| EBITDA Ratio
| 0.177 | 0.155 | 0.136 | 0.221 | 0.258 | 0.173 | 0.193 | 0.19 | 0.221 | 0.174 | 0.243 | 0.259 | 0.253 | 0.183 | 0.191 | 0.253 | 0.207 | 0.196 | 0.231 | 0.314 | 0.251 |